SciSparc stock jumps 202% after NeuroThera wins conditional TSX approval.
SPRC rallies as NeuroThera moves closer to its CliniQuantum acquisition.
NeuroThera’s TSX approval sparks a sharp breakout in SciSparc shares.
SciSparc shares soar after CliniQuantum deal clears a key TSX step.
SPRC surges as NeuroThera advances quantum clinical trial technology deal.
SciSparc Ltd. (SPRC) shares jumped sharply after NeuroThera Labs secured conditional approval from the TSX Venture Exchange. SPRC surged to $13.30, gaining $8.90, or 202.27%, after opening near $4.40. The move followed progress on NeuroThera’s planned acquisition of a controlling stake in CliniQuantum Ltd.
SciSparc said NeuroThera received conditional regulatory approval from the TSX Venture Exchange for the CliniQuantum transaction. The approval moves the deal closer to completion, although final acceptance and other closing steps remain required. NeuroThera operates as SciSparc’s majority-owned subsidiary and focuses on clinical-stage pharmaceutical development.
Under the agreement, NeuroThera will acquire about 54% of CliniQuantum’s issued and outstanding ordinary shares. The deal covers 56,375 CliniQuantum ordinary shares from certain selling shareholders. In return, NeuroThera will issue 56.6 million common shares to those shareholders.
The consideration shares carried an aggregate value of about $9.46 million. That value used NeuroThera’s 20-day volume weighted average trading price on the TSX. Additionally, the companies amended the agreement after TSX review comments on future share issuance terms.
CliniQuantum is a private Israeli technology company focused on clinical trial data analysis. The company uses quantum simulation and quantum Monte Carlo methods to support trial outcome precision. Its platform aims to identify patient groups that respond better to investigational therapies.
The company’s main asset is a license agreement with Quantum X Labs Ltd. That agreement gives CliniQuantum an exclusive worldwide royalty-bearing license in its defined field. The licensed technology covers quantum simulation and quantum Monte Carlo applications for clinical trials.
The licensed patent consists of one United States provisional patent application. The application focuses on generating quantum Markov Chain Monte Carlo sampling points for continuous distribution functions. Therefore, the transaction gives NeuroThera exposure to data-focused tools within clinical research.
NeuroThera and the selling shareholders also extended the transaction outside date to June 1, 2026. The extension gives the parties more time to complete closing conditions. These conditions include an Israeli tax ruling and final TSX acceptance.
The amended agreement also sets a floor price for future common share issuances tied to earn-out payments. NeuroThera agreed that those shares will carry a deemed price of at least $0.05 each. Moreover, selling shareholders must complete lock-up arrangements before the deal closes.
SciSparc develops pharmaceutical assets through NeuroThera and other related operations. Its pipeline includes cannabinoid-based programs targeting Tourette syndrome, Alzheimer’s disease agitation, autism spectrum disorder, and status epilepticus. The company also holds a controlling interest in a hemp seed oil product business on Amazon.
The post SciSparc Ltd. (SPRC) Stock: Shares Soar 202% on NeuroThera’s TSX Approval appeared first on CoinCentral.
